European Union - English - EMA (European Medicines Agency)

bayer animal health gmbh - iron(iii) ion, toltrazuril - toltrazuril, combinations - pigs (piglets) - for the concurrent prevention of clinical signs of coccidiosis (such as diarrhoea) in neonatal piglets on farms with a confirmed history of coccidiosis caused by cystoisospora suis, and prevention of iron deficiency anaemia.

Kenya - English - Pharmacy and Poisons Board

i) iron (iii)-hydroxide polymaltose complex ihs - oral liquid - iron (iii)-hydroxide polymaltose complex… - antianemic preparations - iron preparations: iron

Namibia - English - Namibia Medicines Regulatory Council

actor pharma (pty) ltd - iron (iii)-hydroxide sucrose complex - solution for injection - each 5ml ampoule contains 100mg iron in form of iron (iii)-hydroxide sucrose complex.

Namibia - English - Namibia Medicines Regulatory Council

takeda (pty) ltd - iron iii hydroxide sucrose complex - injection - each ampoule contains iron iii hydroxide sucrose complex equiv. to 100,0mg of iron

Philippines - English - FDA (Food And Drug Administration)

genpharm, inc.; distributor: alberta's pride international indigo, inc. - iron , folic acid (vitamin b9) - capsule - 100 mg (equivalent to 333.33 mg iron (iii) hydroxide polym altose complex)/550 mcg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

healol pharmaceuticals sdn. bhd. - iron(iii) hydroxide polymaltose complex; folic acid; ascorbic acid -

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmacosmos a/s - iron (iii) hydroxide dextran complex - solution for injection/infusion - 50 milligram(s)/millilitre - iron, parenteral preparations

Malta - English - Malta Medicines Authority

fresenius medical care nephrologica deutschland gmbh d-61346 bad homburg, germany - iron - solution for infusion or injection - iron 20 mg/ml - antianemic preparations

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association's diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du